Wuxi Aviation Port and Jiangyin Port received approval from China's National Medical Products Administration to import drugs on Sept 14.
The administration said that the Wuxi market supervision bureau and the Wuxi drug safety inspection and testing center will be responsible for the managing and inspecting of imported drugs in Wuxi.
Officials said the decision will benefit pharmaceutical enterprises by reducing the time and cost associated with the importing of drugs.
Wuxi's pharmaceutical industry has witnessed rapid growth in recent years. In 2019, the total revenue of its biopharmaceutical industry reached 82.5 billion yuan ($12.16 billion). Its growth rate was the highest among the city's strategic emerging industries.
From January to April, the total output value of the city's biopharmaceutical industry exceeded 19.9 billion yuan. The total industrial output value of 108 biomedical manufacturing companies above designated size recorded a year-on-year growth of 9.6 percent to reach 15.94 billion yuan.
Officials from the Wuxi market supervision bureau said they will work with other departments to strengthen management on drug safety and provide comprehensive services related to the import of drugs.
